Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... antibodies against the currently marketed recombinant human erythropoietins, such as epoetin alfa or beta and darbepoetin alfa, thus suppressing the production of red blood cells by the ...
2009 SEP 21 ... to maintain hemoglobin levels in the target range when patients are switched from epoetin alfa or epoetin beta to Hematide. Analysis of efficacy for each study is based ...
2009 SEP 21 ... scientists in Cologne, Germany report. "Anemia was controlled by epoetin alfa and did not cause deviations from the planned chemotherapy schedule. There were no ...
2009 JUL 6 ... (rHuEPO) purchased from Korea, China, and India with the innovator product, Epoetin alfa, manufactured by Amgen Inc. The products were characterized for similarity in the, types ...
2009 AUG 31 ... of 15 007 eligible episodes of care (darbepoetin alfa, 7769 episodes [5587 patients]; epoetin alfa 7238 episodes [5157 patients]) were identified. Fewer claims were observed per episode ...
2009 MAY 4 ... Current study results from the report, 'HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid ...
2009 SEP 14 ... ESA (64% [14/22]) with a mean weekly dose of 70.8 (+/- 68.1) mu g, followed by epoetin alfa (37% [8/22]) with a mean weekly dose of 22,625 (21,232) units. More than one quarter ...
2009 MAY 18 ... To describe the pharmacokinetic profiles of six different dosing regimens for epoetin alfa, and whether more rapid and robust reticulocytosis can be elicited with more frequent ...
2009 MAY 25 ... with erythropoiesis-stimulating agents (ESAs) found that the cumulative ESA cost with Epoetin alfa (EPO) was 29 percent lower than treatment with darbepoetin alfa (DARB). The analysis, ...
2009 AUG 31 ... phase III study to evaluate epoetin zeta, a biosimilar epoetin referenced to epoetin alfa, for the treatment of chemotherapy-induced anaemia in patients with cancer. Safety, ...
2009 SEP 14 ... recent research from the United States, "Two erythropoiesis-stimulating agents (ESAs), epoetin alfa and darbepoetin alfa, are approved for the treatment of chemotherapy-induced anemia in ...
2009 JUN 1 ... in Cologne, Germany report.
" Data for patients treated with epoetin alfa, epoetin beta, or darbepoetin alfa were obtained and analysed by independent ...
2009 AUG 10 ... first-line treatment for many forms of anemia. Chang et al. evaluated the effect of epoetin alfa (40,000 units administered subcutaneously every week) and standard-of-care therapy on ...
2009 AUG 31 ... of Clinical Pharmacology and Therapeutics (Biosimilarity of HX575 (Human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. International Journal of ...
